HOUSE_OVERSIGHT_024032.jpg
1.2 MB
Extraction Summary
0
People
9
Organizations
0
Locations
0
Events
1
Relationships
1
Quotes
Document Information
Type:
Financial report / investment performance summary
File Size:
1.2 MB
Summary
This document is a confidential financial chart titled 'Returns by Fund' as of March 31, 2014, bearing a House Oversight stamp. It details the performance metrics (IRR, Multiples, Capital) for six funds: Growth II HCT, Sprout VII HCT, Sprout VIII HCT, Sprout IX HCT, NLV-I, and NLV-II. The chart compares these funds against public indices like the S&P 500 and Nasdaq, showing significant distributed capital totaling over $1 billion for the largest fund listed.
Organizations (9)
| Name | Type | Context |
|---|---|---|
| New Leaf | ||
| Sprout Funds | ||
| Growth II HCT | ||
| NLV-I | ||
| NLV-II | ||
| S&P 500 | ||
| Russell 3000 | ||
| Nasdaq | ||
| House Oversight Committee |
Relationships (1)
Both fund groups are presented together in the same performance chart and footnote mentions 'NLV and Sprout fund data'.
Key Quotes (1)
"Current gross and net portfolio returns for the New Leaf funds and for the healthcare technology portfolios in the Sprout Funds are detailed in the following chart"Source
HOUSE_OVERSIGHT_024032.jpg
Quote #1
Full Extracted Text
Complete text extracted from the document (2,158 characters)
Current gross and net portfolio returns for the New Leaf funds and for the healthcare technology portfolios in the Sprout Funds are detailed in the following chart:
Chart 1: Returns by Fund
As of March 31, 2014
($ in millions)
As of March 31, 2014
($ in millions)
Fund:
Growth II HCT
Sprout VII HCT
Sprout VIII HCT
Sprout IX HCT
NLV-I
NLV-II
Growth II HCT
Sprout VII HCT
Sprout VIII HCT
Sprout IX HCT
NLV-I
NLV-II
Fund Size:
$15M Fund
$95M Fund
$147M Fund
$690M Fund
$310M Fund
$450M Fund
$15M Fund
$95M Fund
$147M Fund
$690M Fund
$310M Fund
$450M Fund
Paid-In Capital
$15M
$95M
$147M
$690M
$303M
$407M
$15M
$95M
$147M
$690M
$303M
$407M
Vintage Year:
(1993 - 2007)
(1995 - 2011)
(1998 - 2012)
(2000)
(2005)
(2008)
(1993 - 2007)
(1995 - 2011)
(1998 - 2012)
(2000)
(2005)
(2008)
First Investment
1995
1995
1998
2000
2005
2008
1995
1995
1998
2000
2005
2008
Gross Fund Returns
Total Multiple N
4.4x
2.6x
1.7x
2.0x
2.1x
1.8x
Total Multiple N
4.4x
2.6x
1.7x
2.0x
2.1x
1.8x
Realized Multiple N
4.4x
2.6x
1.7x
2.2x
1.7x
2.0x
4.4x
2.6x
1.7x
2.2x
1.7x
2.0x
Total IRR D
44%
19%
10%
15%
19%
30%
44%
19%
10%
15%
19%
30%
Realized IRR D
44%
19%
10%
17%
23%
33%
44%
19%
10%
17%
23%
33%
Net Fund Returns
Net Total Multiple
3.69x
2.17x
1.49x
1.66x
1.75x
1.45x
Net Total Multiple
3.69x
2.17x
1.49x
1.66x
1.75x
1.45x
Net Total IRR D
28.9%
12.0%
6.0%
9.3%
12.0%
16.7%
28.9%
12.0%
6.0%
9.3%
12.0%
16.7%
Net Distributed / Paid-In Multiple F
3.69x
2.17x
1.49x
1.55x
0.51x
0.50x
3.69x
2.17x
1.49x
1.55x
0.51x
0.50x
Net Distributed $s to LPs
$56.3
$207.0
$218.7
$1,071.5
$154.7
$204.2
$56.3
$207.0
$218.7
$1,071.5
$154.7
$204.2
Interim Fund Liquidity Metrics
(Distributed + Public) / Paid-In Multiple G
--
--
--
1.62x
0.74x
1.18x
(Distributed + Public) / Paid-In Multiple G
--
--
--
1.62x
0.74x
1.18x
(Distributed + Liquid Public) / Paid-In Multiple H
--
--
--
1.58x
0.57x
0.75x
--
--
--
1.58x
0.57x
0.75x
IRR Outperformance Versus Public Indices **
PME+ (Basis Points over S&P 500 Healthcare Sector)
+2,064 bps
+302 bps
+441 bps
+776 bps
+201 bps
-187 bps
PME+ (Basis Points over S&P 500 Healthcare Sector)
+2,064 bps
+302 bps
+441 bps
+776 bps
+201 bps
-187 bps
PME+ (Basis Points over S&P 500) **
+2,258 bps
+568 bps
+587 bps
+638 bps
+496 bps
+275 bps
+2,258 bps
+568 bps
+587 bps
+638 bps
+496 bps
+275 bps
PME+ (Basis Points over Russell 3000) **
+2,215 bps
+554 bps
+502 bps
+565 bps
+446 bps
+218 bps
+2,215 bps
+554 bps
+502 bps
+565 bps
+446 bps
+218 bps
PME+ (Basis Points over Nasdaq Composite) **
+2,125 bps
+554 bps
+725 bps
+451 bps
+181 bps
-21 bps
+2,125 bps
+554 bps
+725 bps
+451 bps
+181 bps
-21 bps
NLV and Sprout fund data as of March 31, 2014. Sprout fund statistics computed based on healthcare portfolio within Sprout.
* See Appendix 2 and endnotes A and E in Appendix 4. Based on synthetic funds with assumptions around recycling and fee structure.
** Based on Public Market Equivalent (PME+) methodology. See Appendix 3 and endnotes A, B, E and G in Appendix 4.
Please Section XIII: "Appendices" for definitions of terms and/or methodology.
* See Appendix 2 and endnotes A and E in Appendix 4. Based on synthetic funds with assumptions around recycling and fee structure.
** Based on Public Market Equivalent (PME+) methodology. See Appendix 3 and endnotes A, B, E and G in Appendix 4.
Please Section XIII: "Appendices" for definitions of terms and/or methodology.
21
CONTROL NUMBER 257 - CONFIDENTIAL
HOUSE_OVERSIGHT_024032
CONTROL NUMBER 257 - CONFIDENTIAL
HOUSE_OVERSIGHT_024032
Discussion 0
No comments yet
Be the first to share your thoughts on this epstein document